Eli Lilly in Procurement Deal With EC to Supply Covid-19 Treatment
September 21 2021 - 2:25PM
Dow Jones News
By Stephen Nakrosis
Eli Lilly and Co. on Tuesday said it entered a Joint Procurement
Agreement with the European Commission to supply bamlanivimab and
etesevimab for confirmed cases of Covid-19.
The pharmaceutical company said the deal will see it supply up
to 220,000 doses to treat confirmed cases of Covid-19 in certain
patients aged 12 and older.
The deal allows participating nations in the European Union and
European Economic Area to buy the products directly from Lilly
"following national approval for emergency use, or marketing
authorization at the EU level," the company said.
Alfonso Zulueta, senior vice president and president, Lilly
International, said, "Bamlanivimab and etesevimab have played an
important role in the fight against Covid-19, helping hundreds of
thousands of patients globally." He added "Lilly is pleased to have
reached this agreement with the European Commission which opens the
door for many European countries to access this life-saving
treatment option for patients with Covid-19."
Bamlanivimab administered with etesevimab is available under
emergency pathways in 15 countries around the world to treat
Covid-19, Lilly said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 21, 2021 14:10 ET (18:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024